tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Smart Growth
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
News
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Most Visited Websites
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us

VRTX Stock Latest News

Vertex Pharmaceuticals Gains FDA Approval for Cystic Fibrosis Drug
Company AnnouncementsVertex Pharmaceuticals Gains FDA Approval for Cystic Fibrosis Drug
1d ago
8K
VRTX
Vertex announces FDA approval of Alyftrek
PremiumThe Fly
Vertex announces FDA approval of Alyftrek
1d ago
VRTX
Vertex announces FDA exands approval for Trikafta
PremiumThe Fly
Vertex announces FDA exands approval for Trikafta
1d ago
VRTX
Channel Therapeutics highlights difference between NaV1.7, NaV1.8
PremiumThe Fly
Channel Therapeutics highlights difference between NaV1.7, NaV1.8
1d ago
CHRO
VRTX
Vertex Pharmaceuticals price target lowered to $520 from $566 at BMO Capital
PremiumThe Fly
Vertex Pharmaceuticals price target lowered to $520 from $566 at BMO Capital
1d ago
VRTX
Vertex Pharmaceuticals price target lowered to $441 from $506 at Bernstein
PremiumThe FlyVertex Pharmaceuticals price target lowered to $441 from $506 at Bernstein
1d ago
VRTX
Vertex could be down 10% due to LSR disappointment, says Wells Fargo
Premium
The Fly
Vertex could be down 10% due to LSR disappointment, says Wells Fargo
1d ago
VRTX
Vertex price target lowered to $535 from $600 at H.C. Wainwright
Premium
The Fly
Vertex price target lowered to $535 from $600 at H.C. Wainwright
1d ago
VRTX
Vertex Pharmaceuticals price target lowered to $418 from $509 at Barclays
PremiumThe Fly
Vertex Pharmaceuticals price target lowered to $418 from $509 at Barclays
1d ago
VRTX
Oppenheimer downgrades Vertex after lumbosacral radiculopathy study
PremiumThe Fly
Oppenheimer downgrades Vertex after lumbosacral radiculopathy study
2d ago
VRTX
Vertex Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer
PremiumThe Fly
Vertex Pharmaceuticals downgraded to Perform from Outperform at Oppenheimer
2d ago
VRTX
Vertex Pharmaceuticals price target lowered to $400 from $451 at RBC Capital
PremiumThe Fly
Vertex Pharmaceuticals price target lowered to $400 from $451 at RBC Capital
2d ago
VRTX
Vertex Pharmaceuticals price target lowered to $522 from $545 at BofA
PremiumThe FlyVertex Pharmaceuticals price target lowered to $522 from $545 at BofA
2d ago
VRTX
Vertex Pharma’s suzetrigine meets Phase 2 primary endpoint in radiculopathy
Premium
The Fly
Vertex Pharma’s suzetrigine meets Phase 2 primary endpoint in radiculopathy
2d ago
VRTX
Vertex Pharmaceuticals price target raised to $494 from $490 at Stifel
Premium
The Fly
Vertex Pharmaceuticals price target raised to $494 from $490 at Stifel
5d ago
VRTX
Vertex Pharmaceuticals upgraded to Buy from Hold at Jefferies
PremiumThe Fly
Vertex Pharmaceuticals upgraded to Buy from Hold at Jefferies
12d ago
VRTX
Vertex Pharmaceuticals presents long-term data on CASGEVY at ASH
PremiumThe Fly
Vertex Pharmaceuticals presents long-term data on CASGEVY at ASH
13d ago
VRTX
CMS to work with Vertex, blubird to improve access to therapies, Reuters reports
PremiumThe Fly
CMS to work with Vertex, blubird to improve access to therapies, Reuters reports
16d ago
BLUE
VRTX
CRISPR Therapeutics (NASDAQ:CRSP) Boasts Solid Potential and Limited Risk
PremiumMarket News
CRISPR Therapeutics (NASDAQ:CRSP) Boasts Solid Potential and Limited Risk
23d ago
CRSP
VRTX
American upgraded, Regeneron initiated: Wall Street’s top analyst calls
PremiumThe FlyAmerican upgraded, Regeneron initiated: Wall Street’s top analyst calls
1M ago
O
FN
Vertex Pharmaceuticals initiated with a Buy at Citi
Premium
The Fly
Vertex Pharmaceuticals initiated with a Buy at Citi
1M ago
VRTX
Vertex Pharmaceuticals Faces Integration Challenges in Alpine Acquisition
Premium
Company Announcements
Vertex Pharmaceuticals Faces Integration Challenges in Alpine Acquisition
1M ago
VRTX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >